Company / Accounts Receivable
Arrowhead Pharmaceuticals Accounts Receivable History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$6.8M
FY2025
5-year range
$0 / $10.3M
FY2021-FY2025
Trend
-
vs FY2024
Sector context
#96 of 113
Health Care
What the data says
Arrowhead Pharmaceuticals's accounts receivable of $7M is lower than 85% of companies in the Health Care sector (FY2025). Improved from $0 to $7M over the past 2 years.
Based on SEC 10-K filings.
$7M in FY2025 with a 5-year CAGR of +51.8%.
Improved from $0 to $7M over the past 2 years.
Health Care sector context is included.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- +69.2%
- 5-Year CAGR
- +51.8%
- 10-Year CAGR
- -
Sector benchmark
Bottom 15% in Health CareTop 85% of 113This company $6.8M Sector average $1.1B
▼
-99.4% below sector average
Key checks
Key Insights
- 5-year CAGR of +51.8%, indicating consistent growth.
- Ranks #96 out of 113 companies in the Health Care sector.
- Peak accounts receivable was recorded in FY2021.
- Lowest accounts receivable in the period was in FY2024.
Company context
Key Data Points
- Altman Z-Score 0.43 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $6.8M | - |
| FY2024 | $0 | - |
| FY2023 | $0 | -100.0% |
| FY2022 | $1.4M | -86.3% |
| FY2021 | $10.3M | +1112.2% |
| FY2020 | $846.0K | +27.9% |
| FY2019 | $661.4K | +102.0% |
| FY2018 | $327.4K | +382.9% |
| FY2017 | $67.8K | -9.6% |
| FY2016 | $75.0K | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026